AdnaTest BreastCancerSelect enables the immunomagnetic
enrichment of tumor cells via epithelial and tumor-associated antigens. Antibodies against
epithelial and tumor-associated antigens are conjugated to magnetic beads (Dynabeads) for
labeling of tumor cells in peripheral blood. Labeled cells are extracted by a magnetic particle
concentrator (AdnaMag-L and AdnaMag-S) and are subsequently lysed. The results of the
AdnaTest are generate within 8 hours.
The first lane shows the DNA size standard (DNA-Ladder). Samples 1 and 3 are positive for ERCC1. Sample 2 is negative. Actin is detected in samples 1 to 3. The PCR negative (C-) and positive control (ERCC1) are shown in the last two lanes.
The first lane shows the DNA size standard (DNA-Ladder). Sample 1 is positive for GA733-2, Muc-1 and CA125, samples 3, 4 and 5 are positive for GA733-2 and Muc-1, and sample 6 is positive for GA733-2. Sample 2 is negative. Actin is detected in samples 1 to 6. The PCR negative (C-) and positive control are shown in the last two lanes.
In the first step, the CTCs in the blood are enriched (AdnaTest Select).
This is achieved using antibody-coated magnetic particles (beads). Several antibodies are used,
which bind with high specificity and affinity to the corresponding cancer cells. The enriched cells
are lysed and subsequently purified several times to extract mRNA.
In a second step the enriched cells are examined by RT-PCR for tumor-associated expression
patterns. The mRNA strands are reverse transcribed into cDNA. Subsequently, several tumor-associated markers can be amplified using multiplex PCR and visualized.